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A protocol for custom CRISPR Cas9
donor vector construction to truncate genes
in mammalian cells using pcDNA3 backbone
Neftali Vazquez1†, Lilia Sanchez1†, Rebecca Marks1†, Eduardo Martinez1, Victor Fanniel1, Alma Lopez1,
Andrea Salinas1, Itzel Flores1, Jesse Hirschmann1, Robert Gilkerson1, Erin Schuenzel1, Robert Dearth1,
Reginald Halaby2, Wendy Innis‑Whitehouse3 and Megan Keniry1*

Abstract
Background: Clustered regularly interspaced short palindromic repeat (CRISPR) RNA-guided adaptive immune
systems are found in prokaryotes to defend cells from foreign DNA. CRISPR Cas9 systems have been modified and
employed as genome editing tools in wide ranging organisms. Here, we provide a detailed protocol to truncate genes
in mammalian cells using CRISPR Cas9 editing. We describe custom donor vector construction using Gibson assembly
with the commonly utilized pcDNA3 vector as the backbone.
Results: We describe a step-by-step method to truncate genes of interest in mammalian cell lines using custommade donor vectors. Our method employs 2 guide RNAs, mutant Cas9D10A nickase (Cas9 = CRISPR associated
sequence 9), and a custom-made donor vector for homologous recombination to precisely truncate a gene of
interest with a selectable neomycin resistance cassette (NPTII: Neomycin Phosphotransferase II). We provide a detailed
protocol on how to design and construct a custom donor vector using Gibson assembly (and the commonly utilized
pcDNA3 vector as the backbone) allowing researchers to obtain specific gene modifications of interest (gene trunca‑
tion, gene deletion, epitope tagging or knock-in mutation). Selection of mutants in mammalian cell lines with G418
(Geneticin) combined with several screening methods: western blot analysis, polymerase chain reaction, and Sanger
sequencing resulted in streamlined mutant isolation. Proof of principle experiments were done in several mammalian
cell lines.
Conclusions: Here we describe a detailed protocol to employ CRISPR Cas9 genome editing to truncate genes of
interest using the commonly employed expression vector pcDNA3 as the backbone for the donor vector. Provid‑
ing a detailed protocol for custom donor vector design and construction will enable researchers to develop unique
genome editing tools. To date, detailed protocols for CRISPR Cas9 custom donor vector construction are limited (Lee
et al. in Sci Rep 5:8572, 2015; Ma et al. in Sci Rep 4:4489, 2014). Custom donor vectors are commercially available,
but can be expensive. Our goal is to share this protocol to aid researchers in performing genetic investigations that
require custom donor vectors for specialized applications (specific gene truncations, knock-in mutations, and epitope
tagging applications).
Keywords: CRISPR Cas9, Mammalian cell lines, Custom donor vector design and construction
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Background
A significant proportion of bacteria and archaea (roughly
40 and 90% respectively) employ [1, 2] CRISPR Cas9
mechanisms as an adaptive immunological response
against virus and plasmid foreign DNA [3–10]. Researchers have exploited the CRISPR Cas9 molecular machinery
to target genes in numerous organisms such as yeast, flies,
worms, and mammals leading to groundbreaking discoveries [11–14]. Although other approaches have been utilized
for genome editing for decades, CRISPR Cas9 technology
has reshaped genetic engineering by providing a quick and
facile tool, greatly accelerating research [13, 14].
Endogenous CRISPR Cas9 (and related) systems serve
as an acquired immunological response [3–5, 15–18].
Invading DNA (from plasmids and viruses) becomes
incorporated into the CRISPR locus of the prokaryotic genome. CRISPR loci typically have noncontiguous
direct repeats and spacers that contain the invading DNA
sequences [19]. Transcription of the CRISPR locus produces a pre-crRNA (crRNA = CRISPR RNA) that base
pairs with a trans-activating-crRNA (tracrRNA, also
encoded by CRISPR system), leading to processing and
incorporation into a Cas9-containing complex [20–22].
Many prokaryotes harbor specific endonucleases such as
Cas9 that contain two domains: RuvC-like [an endonuclease domain named for an Escherichia coli (E. Coli) protein involved in DNA repair] and HNH (an endonuclease
domain named for characteristic histidine and asparagine
residues) to cleave foreign DNA [15]. Hybridized crRNA/
tracrRNA serves as a guide for Cas9 to cleave foreign
DNA in a sequence-specific manner. With heterologous
CRISPR Cas9 systems such as those utilized in human
cells, a chimeric guide RNA (gRNA) is employed to target specific sequences [23]. The gRNA contains a fusion
between tracrRNA and crRNA that enables specific targeting of Cas9 to a gene of interest [24].
Employing CRISPR Cas9 technology as a gene editing
tool is a recent development in the field of molecular biology [14, 24]. This tool has already had a transformative
impact on research, allowing for the quick identification
of mutations in wide-ranging experimental settings [23].
However, it has become increasingly evident that utilization of CRISPR Cas9 can lead to off-target effects [19,
25, 26]. CRISPR Cas9 can tolerate base pair mismatches
between the gRNA and target sequences [25, 27, 28].
CRISPR technology utilizes the host DNA repair machinery to resolve DNA lesions, leading to the isolation of
mutations [29]. One issue that we encountered when trying to mutate genes in cancer cell lines, widely reported
by others, was that mutation frequencies vary widely
depending on the methodology employed, the locus being
mutated and screening methods [17, 29]. Chiang et al.
observed mutation efficiencies without selection by green
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fluorescent protein (GFP)-based cell sorting of 1–4% in
HAP1 (near diploid chronic myelogenous leukemia) and
2–22% in U2OS (human bone osteosarcoma epithelial)
cell lines [28, 30–32]. In these settings with low mutation frequencies, methods that employ selection (such as
neomycin resistance) may be necessary to obtain enough
mutants for study in a cost effective manner. Here, we
describe a detailed protocol to construct a custom donor
vector (using the pcDNA3 vector as the backbone) in
order to truncate the gene of interest. We describe a
streamlined screening process to isolate and validate
mutants in settings with low mutation frequencies.

Methods
This protocol can be employed to specifically truncate
genes of interest using a neomycin resistance cassette
(NPTII, enabling selection of mutants with G418) in
mammalian cell lines. Figure 1 shows the basic steps to
truncate the gene of interest. First, a custom donor vector needs to be designed and constructed. Next, CRISPR
Cas9 mutagenesis needs to be performed. Last, mutants
must be isolated and validated. This protocol addresses
multiple barriers found with employing CRISPR Cas9 to
mutate genes. First, we needed to design a custom donor
vector in order to obtain truncation mutants for our
research. Although we found many protocols for CRISPR
mutagenesis, we found a lack of published protocols that
described custom donor vector construction in detail and
purchasing a custom donor vector can be expensive [1,
2]. Secondly, we sought to minimize off-target effects [25,

Truncang FOXO3 gene using CRISPR
Build custom donor vector
using Gibson Assembly

CRISPR Cas9 mutagenesis in
mammalian cell lines with
custom donor vector, 2 guide
RNAs and Cas9 D10A nickase

Screen for putave
mutants and validate
Fig. 1 Flow chart for CRISPR Cas9 mutagenesis using a custom donor
vector. A flow chart for CRISPR mutagenesis with custom donor vec‑
tor is depicted
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28, 30–32]. Finally, we wanted to be able to quickly isolate
mutants for a gene of interest, even if the mutation frequency was low. Many cancer cell lines such as U87MGs
have deficient homologous recombination repair, making
CRISPR mutagenesis inefficient [33, 34]. Our approach
utilized transiently transfected Cas9D10A nickase, two
gRNAs, and a donor vector to disrupt FOXO3 gene coding sequence with a neomycin resistance gene. The custom
donor vector was built using two, separate Gibson assembly cloning steps with the pcDNA3 vector (Figs. 2, 3).

Construction of FOXO3 donor vector using Gibson
assembly
Gibson assembly is an extremely efficient method to
obtain insertions into a plasmid vector of interest [35].
The FOXO3 donor vector was prepared using a two-step
Gibson assembly-based cloning procedure. The complete sequence of the FOXO3 donor vector can be found
in Additional file 1: Figure S1. Figures 2, 3 depict the
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steps employed to prepare a custom FOXO3 donor vector. First, a 418 base pair fragment from the FOXO3 gene
(named FOXO3 Arm 1) was inserted into the pcDNA3
vector just upstream of the neomycin resistance cassette
(NPTII), producing an intermediate vector. In the second sub-cloning step, (shown in Figs. 2, 3) a 750 base pair
FOXO3 fragment (Arm 2) was inserted into the donor
vector.
For optimal results, FOXO3 donor vector sequences
were selected for (1) proximity to genomic nick sites and
(2) sufficient sequence length to permit efficient recombination. It is important to note that there are two nick
sites for FOXO3 in the genome when using 2 gRNAs and
the Cas9D10A nickase. Therefore, the upstream FOXO3
fragment (Arm 1) in the donor vector and downstream
FOXO3 fragment (Arm 2) need to be in regions that are
in positions amenable to recombination with the two
genomic CRISPR nick sites. The FOXO3 donor vector
fragments should be within 20 bases of the nick sites

Donor Vector Construcon using pcDNA3
Cut pcDNA3 vector with DraIII and
purify fragment with spin column

Amplify PCR fragment with flanking
pcDNA3 sequences (near DraIII site)
and purify with spin column

Perform Gibson Assembly reacon to add first
donor vector arm (Arm 1 of FOXO3) to pcDNA3
Isolate sub-clones with FOXO3 Arm 1 and
confirm by sequencing

Cut vector with FOXO3 Arm 1 using BstZ17I
and purify vector using spin column

Amplify PCR fragment with flanking
pcDNA3 sequences (near BstZ17I site)
and purify with spin column

Perform Gibson Assembly reacon to add second
donor vector arm (Arm 2 of FOXO3) to obtain
complete FOXO3 donor vector
Fig. 2 Construction of FOXO3 donor vector. A fragment of FOXO3 (Arm 1) was inserted into the pcDNA3 vector proximal to the DraIII restriction
site by using Gibson assembly. This intermediate vector was called FOXO3 Arm1 and was utilized to make the final FOXO3 donor vector. Another
fragment of FOXO3 (Arm 2) was inserted into the FOXO3 Arm1 vector (by Gibson assembly) to obtain the final FOXO3 donor vector. This vector was
confirmed by Sanger sequencing and employed in CRISPR Cas9 mutagenesis reactions
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nick made by Cas9D10A and FOXO3 gRNA (HSR0001339464)

FOXO3 Gene in
chromosome

+
FOXO3 Donor vector
(pcDNA3-based)

FOXO3
sequence
108663463108663880

FOXO3
sequence
108663921108664670

nick made by Cas9D10A and FOXO3 gRNA (HSL0001339461)

FOXO3
sequence
108663463108663880

Neomycin Resistance Gene
(NPTII)

FOXO3
sequence
108663921108664670

Recombinaon to disrupt FOXO3

FOXO3 gene
disrupted

FOXO3
sequence
108663463108663880

Neomycin Resistance Gene
(NPTII)

FOXO3
sequence
108663921108664670

Fig. 3 Schematic of FOXO3 gene disruption with neomycin resistance cassette (NPTII). Guide RNAs were employed to nick FOXO3 gene in mamma‑
lian cell lines. The lesions were resolved by recombination with a donor vector that contained a neomycin resistance gene (NPTII) flanked by FOXO3
sequences (that were proximal to the CRISPR Cas9-generated nicked strands of FOXO3 in the chromosome)

and should have at least a few hundred base pairs to promote recombination between the donor vector and the
chromosome [26]. In our design, the upstream sequence
used in the donor vector for FOXO3 Arm 1 contained
418 chromosomal FOXO3 base pairs; these sequences
ended seven bases upstream of the gRNA targeting site
in the genome, allowing for 418 base pairs of homology between the donor vector and genome for recombination-mediated repair just before the nick site in the
genome. The distance between the bottom strand and the
top strand nick sites made by CRISPR Cas9 D10A was 51
bases. The donor vector sequences in FOXO3 Arm 1 and
FOXO3 Arm 2 were non-overlapping. The downstream
fragment in the donor vector contained 750 bases that
were homologous to FOXO3 chromosomal DNA (that
extended beyond the second nick site further downstream into the gene) in order to promote recombination;
the second nick site was 12 bases from the start of the
FOXO3 Arm 2.

Step‑by‑step Gibson assembly reactions for the
FOXO3 donor vector
Gibson assembly reactions were performed to insert two
FOXO3 fragments into the pcDNA3 vector at positions
that were on either side of neomycin resistance cassette
(NPTII gene). For the Gibson assembly reaction, there

needed to be identical sequences on the ends of each piece
of DNA that would be physically joined. Therefore, the
ends of each PCR product needed to be identical to the
piece of pcDNA3 vector to which it would be fused. We
added pcDNA3 vector sequences to the 5′ ends of PCR
primers utilized to amplify FOXO3 fragments. Therefore,
FOXO3 gene fragments (PCR products) had pcDNA3
sequences on the ends that corresponded to upstream
and downstream sequences of the utilized restriction sites
(DraIII for Arm1 and BstZ17I for Arm2) in pcDNA3.
Addition of FOXO3 Arm 1 to donor vector

The pcDNA3 vector was cleaved with DraIII (restriction enzyme from NEB, Ipswich, MA) for 2 h at 37 °C.
The restriction digest included 1 µg of the pcDNA3 vector, 4 μL of 10× NEB Cut Smart buffer, 3 μL of DraIII
restriction enzyme and 27 μL of water. After this, 1 μL of
calf intestine phosphatase (CIP) was added to the reaction (from NEB, Ipswich, MA) and incubated for 1 more
hour at 37 °C. The digested and phosphatased vector was
column purified using Qiagen PCR purification system
(Hilden, Germany). DNA was eluted with sterile water
and quantified using a Nanodrop spectrophotometer.
In order to obtain the FOXO3 Arm 1 for sub-cloning,
a PCR product was prepared that had a fragment of the
FOXO3 gene (adjacent to the CRISPR nick sites in the
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genome) with sequences on the end of each primer that
were identical to the pCDNA3 vector next to the DraIII
site; see Table 1 for PCR primer sequences. The FOXO3
fragment was within 20 bases of the nick in the genome
for recombination. This fragment was 418 base pairs in
length, allowing a significant amount of homology to promote recombination between the donor vector and the
nicked chromosome. The FOXO3 fragment was prepared
using Phusion high fidelity polymerase (Thermo-Fisher,
Waltham, MA). The FOXO3 Arm 1 PCR product was
cleaved with DpnI for 3 h to remove plasmid DNA template (used as template for PCR reaction); 2 μL of DpnI
(NEB, Ipswich, MA) were added to unpurified FOXO3
PCR product (still containing nucleotides, polymerase,
etc.) and samples were incubated at 37 °C for 2 h. After
DpnI digestion, the PCR product was column purified
using Qiagen PCR purification system (Hilden, Germany)
and eluted with sterile water. The purified PCR product
was quantified with a Nanodrop spectrophotometer.
Gibson assembly reactions were performed using
10 ng of vector (cut, phosphatased and column purified
pcDNA3) with 80 ng of insert (FOXO3 fragment); the
DNA reactants comprised a volume of 10 μL initially. To
the DNA reactants, 10 μL of NEB Gibson assembly mix
was added for a final volume of 20 μL (NEB, Ipswich,
MA). These reactions were incubated at 50 °C for 1 h
and were then transformed into chemically competent
bacterial cells (5-alpha competent E. coli, NEB, Ipswich,
MA) as directed by the NEB Gibson assembly kit. Transformed bacterial cells were plated in dilutions (1:10, 1:100
and 1:1000) to obtain single colonies given the high efficiency of the Gibson assembly reactions. Single colonies
were screened by restriction digest and confirmed by
Sanger sequencing. The vector obtained from this was
called FOXO3 Arm 1 vector.
Addition of FOXO3 Arm 2 to donor vector

The second arm for the FOXO3 donor vector was prepared in a similar manner to Arm 1. The intermediate
Table 1 PCR Primers utilized to amplify FOXO3 gene frag‑
ments for Donor Vector Gibson Assembly Reactions
Primer

Sequencea

FOXO3 ARM 1 F

5′-GTGCTTTACGGCACCTCGACCCCCCGGCACAACCTGTCACTGC-3′

FOXO3 ARM 1 R

5′-CCGTCTATCAGGGCGATGGCCGCTGTAGAGCAT
GGGCGAGAG-3′

FOXO3 ARM 2 F

5′-CAAATAAAGCATTTTTTTCACTCGGTGGAACTG
CCACGGCTG-3′

FOXO3 ARM 2 R

5′-GAGTTTGGACAAACCACAACTAGGTCCAAGT
CGCTGGGGAAC-3′

a

Nucleotides in bold corresponds to pcDNA3 vector sequences. Sequences in
italics were to amplify the indicated FOXO3 arm
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vector (with FOXO3 Arm 1) was cut with BstZ17I, which
is on the other side of the neomycin resistance gene in
the pcDNA3 plasmid compared to FOXO3 Arm 1. The
cleaved vector was treated with CIP (1 μL CIP, NEB,
Ipswich, MA) for 1 h and subsequently column purified.
FOXO3 Arm 2 was amplified with the primer pair specified in Table 1, producing a product that had sequences
on each end that were identical to the sequences proximal to the BstZ17I site in the intermediate FOXO3 Arm
1 vector. Gibson assembly reactions were performed (as
previously described to sub-clone Arm 1 of FOXO3) to
obtain the final FOXO3 donor vector Figs. 2, 3. Transformed bacterial cells were plated in dilutions (1:10, 1:100
and 1:1000) to obtain single colonies given the extremely
high efficiency of the Gibson assembly reactions. The
complete FOXO3 donor vector was confirmed by restriction fragment analysis and Sanger sequencing. The complete sequence of the FOXO3 donor vector can be found
in Additional file 1: Figure S1.

CRISPR Cas9 mutagenesis to truncate the FOXO3
gene in mammalian cells
Transient transfections to obtain FOXO3 truncation
mutants

Transient transfections were performed using the glioblastoma cell line U87MG, breast cancer cell line BT549,
or human kidney cell line HEK 293, which were obtained
from American Type Culture Collection (ATCC, Manassas, VA) and propagated under standard conditions
[37 °C with 5% CO2 in media specified by ATCC supplemented with 10% FBS (fetal bovine serum) and 5%
penicillin/streptomycin (pen/strep)]. Media employed
to grow U87MG cells was MEM, BT549 was RPMI and
HEK 293 was DMEM. One million cells of each cell
line was transfected using LONZA (nucleofection kit
V, program P-20 for U87MG and BT549 and program
X-001 for HEK 293) and were allowed to recover for
2 days in 10 cm dishes. In each transfection, 250 ng of
each guide RNA (gRNA) vector (Table 2) were added as
well as 250 ng of the vector enabling Cas9D10A expression (CRISPR Cas9D10A-GFP Nickase, catalog: CAS9D10AGFPP, Sigma, St. Louis, MO). Guide RNA vectors
were obtained from Sigma (St. Louis, MO) and were utilized to make DNA nicks in both chromosomal FOXO3
DNA strands (Figs. 2, 3). The FOXO3-containing portions of the gRNAs are detailed in Table 2. A negative
control gRNA (CRISPR Universal Negative Control 1,
catalog: CRISPR06, Sigma, St. Louis MO) was utilized
for control experiments (500 ng per transfection to have
the same amount of DNA as mutagenesis samples). One
microgram of FOXO3 donor vector was utilized in each
transfection.
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Table 2 Guide RNA sequences
Gene

I.D. for construct

Sequence

FOXO3

HSL0001339461

CTTACTGAAGGTGACAGGCTGG

FOXO3

HSR0001339464

CACGGCTGACTGATATGGCAGG

It is important to note that the nicks directed by the
gRNAs are staggered on the chromosome (about 40 base
pairs apart). These gRNAs are used in concert with the
Cas9D10A nickase (CRISPR Cas9D10A-GFP Nickase,
catalog: CAS9D10AGFPP, Sigma, St. Louis, MO) to make
nicks in a gene of interest [26, 28, 30–32]. It has been
shown that Cas9D10A allows for > 100-fold increased
specificity for genomic editing (between 200-fold and
1500-fold based on deep sequencing experiments) [26].
For each mutagenesis, cells that survived the transfection (after 2 days of recovery) were incubated in 0.25%
trypsin for 3 min and were placed into 10 mL of MEM
(contained 10% FBS and 5% Pen/Strep). Ten plates of
diluted cells (approximately 100,000 cells per 10 cm
dish) were prepared from this mixture. G418 (0.5 mg/
mL final concentration for U87MG and BT549 and
1.5 mg/mL G418 for HEK 293 cells) was added to each
10 cm plate 1 day after plating. Single clones were isolated from these selected dishes 4 weeks later using cloning cylinders. 2–10 single colonies were obtained from
each 10 cm plate. To clone a colony, the plate was washed
with 2 mL 0.25% trypsin and aspirated. Cloning cylinders
(Fisher: 0955221) were placed onto the 10 cm plate using
sterile forceps and vaseline (to make the cylinder stick
to the plate). 200 μL of 0.25% trypsin was added to each
cylinder and incubated for 5 min. The 200 μL of trypsin
was pipetted up and down ten times and then plated into
2 mL of fresh media in a well of a six well plate.

Results
Western blot analysis with putative FOXO3 mutants

Proof-of-principle studies were done to determine mutation frequencies using our described protocol in several
mammalian cell lines: U87MG, BT549 and HEK 293.
Figure 4 depicts the encoded FOXO3 truncation mutant
protein. FOXO3 is an extensively characterized transcriptional activator that impacts metabolism, the cell cycle,
apoptosis and cell fate [36–38]. Disruption of the FOXO3
gene led to the production of a truncated mutant protein that contained the first 349 amino acids of FOXO3
(including the DNA binding domain); most of the transactivation domain was deleted. CRISPR Cas9 mutagenesis followed by selection with neomycin with U87MG
cells allowed our group to isolate 77 putative mutants
in one trial and 50 putative mutants in another. We confirmed the truncation mutants in several ways. Western
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blot analyses were performed as described previously
[39]. Expression of FOXO3 was assessed by western
blot analysis. Total protein was obtained from U87MG
cells by rinsing out the 6 well plate wells with 1XPBS
followed by directed lysis in 2× sample buffer (125 mM
Tris–HCL at pH 6.8, 2% sodium dodecyl sulfate (SDS),
10% 2-mercaptoethanol, 20% glycerol, 0.05% bromophenol blue, 8 M urea); 2× sample buffer was added to each
well and scraped. The lysate was collected from each well,
placed into 1.5 mL microcentrifuge tubes and heated for
10 min at 90 °C in a dry-bath heat block. Equal amounts
of protein lysates were separated by sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) electrophoresis at
100 V for 1 h. The protein was then transferred onto a
polyvinylidene fluoride (PVDF) membrane for an hour
and 30 min then blocked in a 5% milk solution [carnation powdered milk, 1× tri-buffered saline with Tween
20 (TBST)] for an hour. The membrane was incubated
with FOXO3 (Cell Signaling, Danvers, MA, Cat: 75D8),
or GAPDH (Santa Cruz Biotechnology, Dallas, TX, cat:
G-9) antibodies overnight at 4 °C then washed for 20 min
with TBST in 5-min intervals. The blot was incubated
with secondary antibodies. The membrane was washed
again for 20 min in 5-min intervals and allowed to
develop using SuperSignal West Dura Extended Duration
Substrate luminol solution for 5 min. The BioRad ChemDoc XRS+ molecular imager was used to detect light
emitted from protein—containing complexes. Western
blot SCN files from the (BioRad ChemDoc XRS+) were
analyzed using NIH Image J.
Western blot analysis showed that FOXO3 truncation mutant protein was much smaller than the wildtype FOXO3, roughly 45 kDa (kilo Dalton) versus the
full-length 80 kDa, Fig. 4. In our first attempt to isolate
FOXO3 disruption mutants, we screened 77 putative
clones and obtained four homozygous mutants based on
western blot analysis, Fig. 4. Therefore, 5% of the screened
isolates were homozygous mutant. In a repeat proof-ofprinciple experiment, we found that out of 50 screened
putative mutants, three had only the truncated form of
FOXO3 as evidenced by the 45 kDa band (6% homozygous mutation rate), Fig. 5. Three samples had both the
truncated form of FOXO3 and the full-length FOXO3
protein (two bands that were 45 and 80 kDa), Fig. 5. 44
out of the 50 screened samples had full-length FOXO3
protein (only 80 kDa band), Fig. 5. Therefore, even with
selection, there was a low mutation rate (5–6%). This was
not surprising given the DNA repair deficiency found in
U87MG cells [33, 34]. We also screened for FOXO3 truncation mutants in two additional cell lines: breast cancer
BT549 and human kidney HEK 293. Out of 56 screened
isolates in BT549 cells, five were homozygous mutant
(approximately 9%), Table 3. We found that only one of
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a

Wild-type FOXO3 protein (673 a.a.)

CRISPR mutagenesis

25 kDa

Mutant 4

Mutant 3

Mutant 2

100 kDa
75 kDa
50 kDa

Mutant 1

b

Control

Truncated FOXO3 protein (349 a.a.)

Wild-type FOXO3
Truncated FOXO3
FOXO3 western blot
GAPDH western blot

Fig. 4 FOXO3 truncation mutant proteins retain the DNA binding domain. a Disruption of the FOXO3 gene as described in “Methods” led to a
truncated protein that was 349 amino acids in length. This mutant protein retained the FOXO3 DNA binding domain, but lacked the transactivation
domain. b Total protein lysates prepared from FOXO3 mutant-containing cells and control cells were examined by western blot analysis; employed
antibodies are indicated. Wild-type FOXO3 was approximately 80 kDa, whereas, mutant FOXO3 protein was approximately 45 kDa. Out of 77 puta‑
tive mutants screened, only four were homozygous mutant (confirmed by Sanger sequencing)

77 putative mutants screened in HEK 293 background
was homozygous for FOXO3 truncation, Table 3. Therefore the mutant frequency was between 1.3 and 9% in the
tested cell lines.
In our experiments, we were able to screen for a change
in protein size. Other applications of this protocol could
use similar screening techniques when the mutation
frequency is low. Attachment of a GFP fusion to a gene
of interest could be screened by western blot analysis,
microscopy or flow cytometric analysis. Alternatively,
genes could be deleted, leading to a loss of a protein of
interest in western blot analysis. The ability to select
mutants with neomycin and then screen using western
blot analysis (or other technique) greatly facilitates the
isolation of mutants.

Genotyping CRISPR Cas9 mutants
All putative homozygous FOXO3 disruption mutants
that were identified by western blot analyses (Figs. 4,
5, and Table 3) were further confirmed using PCR and
were later confirmed by Sanger sequencing. DNA was

isolated from 1 million cells from each clone. The cells
were removed from plates using trypsin and centrifuged
at 700×g for 5 min. Cells were re-suspended in 500 μL
of Buffer (10 mM Tris 7.4, 10 mM NaCl, 25 mM EDTA,
1% SDS). 25 μL of Proteinase K (50 U/mL stock, catalog:
03115828001, Roche, Mannheim, Germany) was added
to each sample followed by an 18 h incubation at 37 °C.
Next, the sample was extracted with an equal volume of
phenol, followed by centrifugation at top speed in phase
lock tubes (Quanta Biosciences, Beverley, MA, catalog:
2302820). DNA was precipitated from the supernatant
by adding 3 μL of 20 mg/mL glycogen, 50 μL of sodium
acetate and 1 mL of 100% ethanol (stored at − 80 °C overnight followed by 20 min of centrifugation at 17,000×g).
The DNA pellets were washed with 70% ethanol, dried
and re-suspended in sterile water. PCR was performed
to identify clones that had NPTII integration into the
FOXO3 locus using the primers in Table 4. The forward
primer for PCR was approximately sixty bases upstream
of the FOXO3 fragment found in Arm 1 of the FOXO3
donor vector. Therefore, the primer sequences employed

Vazquez et al. BMC Molecular Biol (2018) 19:3
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11
12
13
14
15
16
17
18
19
20

1
2
3
4
5
6
7
8
9
10

Screening for FOXO3 disrupon mutants in U87MG cells

75 kDa
50 kDa

Anbody
FOXO3

30
31
32
33
34
35
36
37
38
39

29

28

27

26

25

24

23

22

21

GAPDH

FOXO3

75 kDa
50 kDa

50

49

48

47

46

40
41
42
43
44
45

GAPDH

FOXO3

75 kDa
50 kDa

GAPDH
Fig. 5 Western blot screening for putative FOXO3 truncation mutants. Total protein lysates were prepared from 50 putative FOXO3 mutant-contain‑
ing cells and were examined by western blot analyses; employed antibodies are indicated. Wild-type FOXO3 was approximately 80 kDa, whereas,
mutant FOXO3 protein was approximately 45 kDa. This second proof of principle screen examined 50 potential FOXO3 mutant clones. Three of
these were homozygous mutant (16, 25 and 43), three appeared to be heterozygous (14, 30 and 31) and 44 were wild-type. The homozygous
mutants were confirmed by Sanger sequencing

Table 3 CRISPR Cas9 mutation frequencies in mammalian
cell lines
Cell line

G418-resistant
isolates screened
by western blot
analysis

U87MG Trial 1

77

4a

U87MG Trial 2

50

3a

6

BT549

56

5

9

HEK293

77

1

1.3

a

Number
of homozygous
truncation
mutants

Homozygous
mutation
frequency
(%)
5

These mutants are shown in western blot analyses found in Figs. 4, 5

Table 4 Primers utilized to detect and sequence FOXO3
gene disruption
Primer name

Sequence

FOXO3 F (for detection of disruption)

5′-GTGCTTCAGGATCGCTTCA-3′

Neo cassette R (for detection of
disruption)

5′-TGCATGCTTTGCATACTTCTG-3′

FOXO3 seq. (for sequencing disruption 5′-CTCGGTTTTGGACCATTCTG-3′
mutants)

for mutant detection by PCR were absent from the donor
vector and were only found in chromosomal FOXO3. The
reverse primer was part of the NPTII cassette used to disrupt FOXO3. Most of the negative samples were positive
for intact vector integration (data not shown). The PCR
products (employed for detecting FOXO3 disruption)
were column purified using Qiagen PCR purification system (Hilden, Germany) and eluted with sterile water. The
purified PCR product was quantified with a Nanodrop
spectrophotometer. Purified PCR products were analyzed by Sanger sequencing; a primer containing FOXO3
chromosomal sequences (that were not present in the
donor vector) was utilized, Table 4. Sanger sequencing
confirmed that the homozygous FOXO3 mutants identified by western blot analyses had the designed gene
disruptions.

Discussion
CRISPR Cas9 technology is an emergent genome editing
tool. Here, we describe a protocol to disrupt the FOXO3
gene in mammalian cells using a neomycin cassette. To
decrease off-target effects, we employed 2 guide RNAs,
a mutant Cas9D10A nickase and a FOXO3 donor vector that was constructed by Gibson assembly (to enable
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the selection of mutants with G418). Selected mutants
were validated by PCR, Sanger sequencing and western
blot analysis. This protocol could be adapted to readily
disrupt or modify genes of interest in order to alter the
genetic background of mammalian cell lines in a directed
manner. The ability to select for the disruption of genes
using neomycin resistance accelerates mutant isolation,
especially when mutation frequencies are low or when
mutations are deleterious to cells.
Many cancer cell lines including U87MGs have deficient DNA repair [33, 34]. Homozygous mutation frequencies varied depending on the cell line as seen in
Table 3. We found that even with selection, 5–6% of
screened putative mutants were homozygous for FOXO3
disruption in U87MG cells (Figs. 4, 5, Table 3). BT549
breast cancer cells had the highest efficiency of 9%.
HEK 293 cells had the lowest homozygous mutation
frequency of only 1.3% (Table 3), whereas many heterozygous mutants were obtained for this cell line (8 out
of 77 screened by western blot, data not shown). Similar homology directed repair (HDR) frequencies were
observed in HEK 293 backgrounds (0.2–1.5%) with the
Cas9 D10A nickase in previous studies [24, 40, 41]. HDR
frequencies using CRISPR Cas9 vary depending on the
cell line, enzymes utilized (Cas9 D10A versus wild-type
Cas9), transfection protocols employed, specific guide
RNAs employed (including PAM sequence variances)
and the specific locus being mutated [23, 27, 29, 40]. It
was surprising that U87MG and BT549 cell lines had
higher gene disruption frequencies than HEK 293 cells.
Perhaps NHEJ more efficiently resolved the Cas9-derived
nicks in HEK 293 cells, leading to lower homology
directed repair in this setting. NHEJ frequencies were
found to be higher than HDR frequencies in 293 backgrounds (50–60% compared to 1%, respectively) [40]. In
addition, BT549 and U87MG cells harbor null mutations
in the tumor suppressor PTEN, which impacts DNA
repair via numerous mechanisms in a context-dependent
manner [33, 43–46]. Loss of PTEN hinders DNA repair,
which may shift double strand break resolution to favor
HDR over NHEJ in U87MG and BT549 cell lines [33].

Conclusions
We describe a CRISPR Cas9 genome editing protocol
for mammalian cell lines by constructing and employing
a custom donor vector that contains a neomycin resistance cassette. We provide a detailed, step-by-step protocol for donor vector design and construction using the
pcDNA3 vector [47]. Custom donor vectors can be difficult to clone and expensive to purchase. We provide a
simple, efficient protocol to obtain custom donor vectors
from the common pcDNA3 mammalian expression vector. We also provide step-by-step instructions on how to
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select mutants and isolate clones. This protocol will allow
researchers to overcome the barrier of low mutation efficiency commonly found in mammalian cell lines. Importantly, researchers can employ this protocol to build
custom donor vectors in order to study novel gene functions and/or examine the localization of tagged proteins
using endogenous expression levels.

Additional file
Additional file 1: Figure S1. FOXO3 donor vector complete sequence.
The complete sequence of FOXO3 donor vector is provided. FOXO3 Arm 1
and Arm 2 are indicated. NPTII (neomycin resistance cassette) is indicated.
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